Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tipifarnib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA known ✓ | P49354 | 15/20 | 0.80 |
| ▸ | FNTB known ✓ | P49356 | 15/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.76 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tipifarnib SCHEMBL22772860 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| (S)-Tipifarnib SCHEMBL30436988 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL94807 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL29371885 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL8097 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL29352433 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL23633189 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| (S)-Tipifarnib SCHEMBL4429738 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL22468601 | 0.96 | FNTA (0.74) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL12021666 | 0.95 | FNTA (0.72) | FNTAFNTBCYP3A4PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12553027-B2 | Generation and cryopreservation of pluripotent stem cell-derived clinical grade corneal endothelial cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250262211-A1 | COMBINATION OF RAS INHIBITORS AND FARNESYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCERS | INSTITUT CLAUDIUS REGAUD (FR) | 2025-08-21 | — | — | US | disclosed |
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4514356-A1 | COMBINATION OF RAS INHIBITORS AND FARNESYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-03-05 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Thereapeutics Pty LTD (AU) | 2025-02-20 | — | — | US | disclosed |
| EP-4504192-A1 | METHODS OF TREATING HEAD AND NECK SQUAMOUS CELL CARCINOMA | Kura Oncology, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119053604-A | Heterocyclic compounds for the treatment of ERK5 mediated diseases | 癌症研究技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-3708166-B1 | THERAPEUTIC AGENT FOR MENTAL RETARDATION OR AUTISM | TOKYO METROPOLITAN INST MEDICAL SCIENCE (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-7456287-B2 | Diastereoselective synthesis process for the preparation of imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-25 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1758885-B1 | DIASTEREOSELECTIVE ADDITION OF LITHIATED N-METHYLIMIDAZOLE ON SULFINIMINES | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-18 | — | — | EP | disclosed |
| US-20070293679-A1 | Diastereoselective Addition of Lithiated N-Methylimidazole on Sulfinimines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293680-A1 | For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293679-A1 | Diastereoselective Addition of Lithiated N-Methylimidazole on Sulfinimines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-20 | — | — | US | disclosed |
| US-20070238880-A1 | Diastereoselective Synthesis Process for the Preparation of Imidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-11 | — | — | US | disclosed |
| US-20070093449-A1 | Novel IV formulation of tipifarnib | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093449-A1 | Novel IV formulation of tipifarnib | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | FNTA 4379/4885FNTB 4047/4885CYP3A4 2471/4885 |
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | FNTA 4507/4885FNTB 3379/4885CYP3A4 3158/4885 |
| US-12553027-B2 | Generation and cryopreservation of pluripotent stem cell-derived clinical grade corneal endothelial cells | CD14, NGF, NEFM | FNTA 2180/4885FNTB 2553/4885CYP3A4 3263/4885 |
| US-20070293680-A1 | For the preparation of (R)-(+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl2(1H)-quinolinone; farnesyl tranferase inhibitory activity | FNTB, CYP4F2, FNTA | FNTA 3/4885FNTB 1/4885CYP3A4 496/4885 |
| US-20070093449-A1 | Novel IV formulation of tipifarnib | FLT4, F5, FLT1 | FNTA 280/4885FNTB 699/4885CYP3A4 638/4885 |
| US-20070238880-A1 | Diastereoselective Synthesis Process for the Preparation of Imidazole Compounds | DHPS, CYP2S1, CYP1A2 | FNTA 1134/4885FNTB 1198/4885CYP3A4 17/4885 |
| US-20250262211-A1 | COMBINATION OF RAS INHIBITORS AND FARNESYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCERS | KRAS, FNTA, NRAS | FNTA 2/4885FNTB 4/4885CYP3A4 2819/4885 |
| US-20070293679-A1 | Diastereoselective Addition of Lithiated N-Methylimidazole on Sulfinimines | SULT1A1, SULT1E1, CSNK1A1L | FNTA 4242/4885FNTB 3766/4885CYP3A4 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.